Clinical trial · Interventional
Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome
Effect of Raloxifene on Ovulation in Women With Polycystic Ovarian Syndrome.
NCT01607320CI-TRIAL-00034981PCOSterminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Over budget, slow recruitment, and personnel change
Summary
Brief summary (as posted)
This study examines Raloxifene versus Clomiphene to induce ovulation in women with polycystic ovarian syndrome (PCOS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clomiphene | Drug | — | UNRESOLVED |
| Raloxifene | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Raloxifene
- description
- 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
- interventionNames
- Drug: Raloxifene
- type
- ACTIVE_COMPARATOR
- label
- Clomiphene
- description
- 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
- interventionNames
- Drug: Clomiphene
Primary outcomes (1)
- measure
- Pregnancy
- timeFrame
- 4 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 36 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women aged 18 to 36 2. BMI \> 19 \& \< 40 3. PCOS diagnosis as evidenced by: Oligo- and/or anovulation (\< 6 cycles per year) and one of the following: * Clinical and/or biochemical signs of hyperandrogenism * Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome) Exclusion Criteria: 1. Use of ovulation induction agents within the past 6 months 2. Positive pregnancy test before taking study medications 3. History or current thromboembolic disorder 4. Coronary artery disease such as heart attack or stroke 5. Tobacco use or history within the past 6 months 6. History of pelvic inflammatory disease and tubal factor infertility 7. Congenital adrenal hyperplasia 8. Diabetes Mellitus * Any subject on Metformin must "wash out" for 30 days prior to screening 9. History of endometriosis 10. Known male factor infertility
References
Publications (0)
Data not yet available
No reference posted for this study.